<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RANITIDINE HYDROCHLORIDE- ranitidine hydrochloride injection </strong><br>Cadila Healthcare Limited<br></p></div>
<h1>Ranitidine Injection, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID1"></a><a name="section-1"></a><p></p>
<p class="First"><a name="ID2"></a><span class="Bold">PRESCRIBING INFORMATION</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID3"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><a name="ID4"></a>The active ingredient in ranitidine injection is ranitidine hydrochloride (HCl), a histamine H<span class="Sub">2</span>-receptor antagonist. Chemically it is N[2-[[[5[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N′-methyl-2-nitro-1,1-ethenediamine, hydrochloride. It has the following structure:</p>
<div class="Figure">
<img alt="formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9268c1df-bcf3-4899-896d-044492802a33&amp;name=ranitidininjmanufact-figure-01.jpg"><p class="MultiMediaCaption">figure01</p>
</div>
<p><a name="ID6"></a>The molecular formula is C<span class="Sub">13</span>H<span class="Sub">22</span>N<span class="Sub">4</span>O<span class="Sub">3</span>S•HCl, representing a molecular weight of 350.87.</p>
<p>Ranitidine hydrochloride, USP is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, granular substance that is soluble in water.</p>
<p>Ranitidine injection, USP is a clear, colorless to yellow, nonpyrogenic liquid. The yellow color of the liquid tends to intensify without adversely affecting potency. The pH of the injection solution is 6.7 to 7.3.</p>
<p><span class="Bold">Sterile Injection for Intramuscular or Intravenous Administration </span></p>
<p>Each 1 mL of aqueous solution contains ranitidine 25 mg (as the hydrochloride); phenol 5 mg as preservative; and 0.96 mg of monobasic potassium phosphate and 2.4 mg of dibasic sodium phosphate as buffers.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID7"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><a name="ID8"></a>Ranitidine hydrochloride is a competitive, reversible inhibitor of the action of histamine at the histamine H<span class="Sub">2</span>-receptors, including receptors on the gastric cells. Ranitidine hydrochloride does not lower serum Ca++ in hypercalcemic states. Ranitidine hydrochloride is not an anticholinergic agent.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="ID9"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
</div>
<div class="Section">
<a name="ID10"></a><a name="section-3.2"></a><p></p>
<h2>Absorption</h2>
<p class="First"><a name="ID11"></a>Ranitidine hydrochloride is absorbed very rapidly after intramuscular (IM) injection. Mean peak levels of 576 ng/mL occur within 15 minutes or less following a 50 mg IM dose. Absorption from IM sites is virtually complete, with a bioavailability of 90% to 100% compared with intravenous (IV) administration. Following oral administration, the bioavailability of ranitidine is 50%. </p>
</div>
<div class="Section">
<a name="ID12"></a><a name="section-3.3"></a><p></p>
<h2>Distribution</h2>
<p class="First"><a name="ID13"></a>The volume of distribution is about 1.4 L/kg. Serum protein binding averages 15%.</p>
</div>
<div class="Section">
<a name="ID14"></a><a name="section-3.4"></a><p></p>
<h2>Metabolism</h2>
<p class="First"><a name="ID15"></a>In humans, the N-oxide is the principal metabolite in the urine; however, this amounts to &lt;4% of the dose. Other metabolites are the S-oxide (1%) and the desmethyl ranitidine (1%). The remainder of the administered dose is found in the stool. Studies in patients with hepatic dysfunction (compensated cirrhosis) indicate that there are minor, but clinically insignificant, alterations in ranitidine half-life, distribution, clearance, and bioavailability.</p>
</div>
<div class="Section">
<a name="ID16"></a><a name="section-3.5"></a><p></p>
<h2>Excretion</h2>
<p class="First"><a name="ID17"></a>Following IV injection, approximately 70% of the dose is recovered in the urine as unchanged drug. Renal clearance averages 530 mL/min, with a total clearance of 760 mL/min.</p>
<p>The elimination half-life is 2.0 to 2.5 hours.</p>
<p>Four patients with clinically significant renal function impairment (creatinine clearance 25 to 35 mL/min) administered 50 mg of ranitidine intravenously had an average plasma half-life of 4.8 hours, a ranitidine clearance of 29 mL/min, and a volume of distribution of 1.76 L/kg. In general, these parameters appear to be altered in proportion to creatinine clearance (see <span class="Bold"><a href="#ID112">DOSAGE AND ADMINISTRATION</a>).</span></p>
</div>
<div class="Section">
<a name="ID18"></a><a name="section-3.6"></a><p></p>
<h2>Geriatrics</h2>
<p class="First"><a name="ID19"></a>The plasma half-life is prolonged and total clearance is reduced in the elderly population due to a decrease in renal function. The elimination half-life is 3.1 hours (see <span class="Bold">PRECAUTIONS: <a href="#ID88">Geriatric Use</a></span>and <span class="Bold">DOSAGE AND ADMINISTRATION: <a href="#ID124">Dosage Adjustment for Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a>).</span></p>
</div>
<div class="Section">
<a name="ID20"></a><a name="section-3.7"></a><p></p>
<h2>Pediatrics</h2>
<p class="First"><a name="ID21"></a>There are no significant differences in the pharmacokinetic parameter values for ranitidine in pediatric patients (from 1 month up to 16 years of age) and healthy adults when correction is made for body weight. The pharmacokinetics of ranitidine hydrochloride in pediatric patients are summarized in Table 1.</p>
<a name="ID22"></a><table width="100%">
<caption><span>Table 1Ranitidine Pharmacokinetics in Pediatric Patients Following IV Dosing</span></caption>
<col width="30%">
<col width="7%">
<col width="17%">
<col width="11%">
<col width="11%">
<col width="24%">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" align="left" colspan="1" valign="top">
<span class="Bold">Population </span><span class="Bold"><br></span><span class="Bold">(</span><span class="Bold">age</span><span class="Bold">) </span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="bottom">
<span class="Bold">n</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">Dose </span><span class="Bold"><br></span><span class="Bold">(</span><span class="Bold">mg</span><span class="Bold">/</span><span class="Bold">kg</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">t</span><span class="Bold"><span class="Sub">½</span> </span><span class="Bold">(</span><span class="Bold">hours</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">Vd </span><span class="Bold">(</span><span class="Bold">L</span><span class="Bold">/</span><span class="Bold">kg</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">CLp </span><span class="Bold"><br></span><span class="Bold">(</span><span class="Bold">mL</span><span class="Bold">/</span><span class="Bold">min</span><span class="Bold">/</span><span class="Bold">kg</span><span class="Bold">)</span><span class="Bold"><br></span>
</td>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="6">
<p class="First Footnote">T<span class="Sub">½</span> = Terminal half-life; CLp = Plasma clearance of ranitidine.<br></p>
<p class="Footnote">ECMO = extracorporeal membrane oxygenation.<br></p>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Peptic ulcer disease <br>(&lt;6 years) <br>(6 to 11.9 years) <br>(&gt;12 years) <br>Adults <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">6 <br> 11 <br> 6<br>6<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">1.25 or 2.5 <br> 1.25 or 2.5 <br> 1.25 or 2.5<br>2.5<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">2.2<br>2.1<br>1.7<br>1.9<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">1.29 <br> 1.14 <br> 0.98 <br> 1.04<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">11.41<br>8.96<br>9.89<br>8.77<br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Peptic ulcer disease <br>(3.5–16 years) <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">12<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.13 to 0.80<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.8<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2.3<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">795 mL/min/1.73/m<span class="Sup">2</span><br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Children in intensive care (1 day–12.6 years) <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">17<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.0<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2.4<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">11.7<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Neonates receiving <br>ECMO <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">12<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6.6<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.8<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4.3<br>
</td>
</tr>
</tbody>
</table>
<p><a name="ID23"></a>Plasma clearance in neonatal patients (less than 1 month of age) receiving ECMO was considerably lower (3 to 4 mL/min/kg) than observed in children or adults. The elimination half-life in neonates averaged 6.6 hours as compared to approximately 2 hours in adults and pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID24"></a><a name="section-3.8"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First"><a name="ID25"></a>Serum concentrations necessary to inhibit 50% of stimulated gastric acid secretion are estimated to be 36 to 94 ng/mL. Following single IV or IM 50 mg doses, serum concentrations of ranitidine are in this range for 6 to 8 hours.</p>
</div>
<div class="Section">
<a name="ID26"></a><a name="section-3.9"></a><p></p>
<h2>Antisecretory Activity</h2>
<ol><li><span class="Bold Italics">Effects on Acid Secretion</span></li></ol>
<p class="First"><a name="ID28"></a>Ranitidine injection inhibits basal gastric acid secretion as well as gastric acid secretion stimulated by betazole and pentagastrin, as shown in Table 2.</p>
<a name="ID29"></a><table width="100%">
<caption><span>Table 2 Effect of Intravenous Ranitidine Hydrochloride on Gastric Acid Secretion</span></caption>
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<thead>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" colspan="1" valign="top"><span class="Bold"><br></span></td>
<td class="Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">Time </span><span class="Bold">After </span><span class="Bold">Dose</span><span class="Bold">, </span><span class="Bold"><br></span><span class="Bold">hours</span><span class="Bold"><br></span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">% </span><span class="Bold">Inhibition </span><span class="Bold">of </span><span class="Bold">Gastric </span><span class="Bold">Acid </span><span class="Bold">Output </span><span class="Bold">by </span><span class="Bold">Intravenous </span><span class="Bold">Dose</span><span class="Bold">, </span><span class="Bold">mg</span><span class="Bold"><br></span><span class="Bold"><br></span>
</td>
<td class="Botrule Toprule" align="left" colspan="1" valign="top"><br></td>
<td class="Botrule Rrule Toprule" align="left" colspan="1" valign="top"><br></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" colspan="1" valign="top"><br></td>
<td class="Botrule Lrule Rrule" align="center" colspan="1" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">20 </span><span class="Bold">mg</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">60 </span><span class="Bold">mg</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">100 </span><span class="Bold">mg</span><span class="Bold"><br></span>
</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Betazole<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Up to 2<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">93<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">99<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">99<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Pentagastrin<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Up to 3<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">47<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">66<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">77<br>
</td>
</tr>
</tbody>
</table>
<p><a name="ID30"></a>In a group of 10 known hypersecretors, ranitidine plasma levels of 71, 180, and 376 ng/mL inhibited basal acid secretion by 76%, 90%, and 99.5%, respectively.</p>
<p>It appears that basal- and betazole-stimulated secretions are most sensitive to inhibition by ranitidine hydrochloride, while pentagastrin-stimulated secretion is more difficult to suppress.</p>
<ol><li><span class="Bold"><span class="Italics">Effects on Other Gastrointestinal Secretions</span></span></li></ol>
</div>
<div class="Section">
<a name="ID32"></a><a name="section-3.10"></a><p></p>
<h2>Pepsin</h2>
<p class="First"><a name="ID33"></a>Ranitidine hydrochloride does not affect pepsin secretion. Total pepsin output is reduced in proportion to the decrease in volume of gastric juice.</p>
</div>
<div class="Section">
<a name="ID34"></a><a name="section-3.11"></a><p></p>
<h2>Intrinsic Factor</h2>
<p class="First"><a name="ID35"></a>Ranitidine hydrochloride has no significant effect on pentagastrin-stimulated intrinsic factor secretion.</p>
</div>
<div class="Section">
<a name="ID36"></a><a name="section-3.12"></a><p></p>
<h2>Serum Gastrin</h2>
<p class="First"><a name="ID37"></a>Ranitidine hydrochloride has little or no effect on fasting or postprandial serum gastrin.</p>
</div>
<div class="Section">
<a name="ID38"></a><a name="section-3.13"></a><p></p>
<h2>Other Pharmacologic Actions</h2>
<ol>
<li>Gastric bacterial flora―increase in nitrate-reducing organisms, significance not known.</li>
<li>Prolactin levels―no effect in recommended oral or IV dosage, but small, transient, dose-related increases in serum prolactin have been reported after IV bolus injections of 100 mg or more.</li>
<li>Other pituitary hormones―no effect on serum gonadotropins, TSH, or GH. Possible impairment of vasopressin release.</li>
<li>No change in cortisol, aldosterone, androgen, or estrogen levels.</li>
<li>No antiandrogenic action.</li>
<li>No effect on count, motility, or morphology of sperm.</li>
</ol>
</div>
<div class="Section">
<a name="ID40"></a><a name="section-3.14"></a><p></p>
<h2>Pediatrics</h2>
<p class="First"><a name="ID41"></a>The ranitidine concentration necessary to suppress basal acid secretion by at least 90% has been reported to be 40 to 60 ng/mL in pediatric patients with duodenal or <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span>.</p>
<p>In a study of 20 critically ill pediatric patients receiving ranitidine IV at 1 mg/kg every 6 hours, 10 patients with a baseline pH ≥4 maintained this baseline throughout the study. Eight of the remaining 10 patients with a baseline of pH ≤2 achieved pH ≥4 throughout varying periods after dosing. It should be noted, however, that because these pharmacodynamic parameters were assessed in critically ill pediatric patients, the data should be interpreted with caution when dosing recommendations are made for a less seriously ill pediatric population.</p>
<p>In another small study of neonatal patients (n = 5) receiving ECMO, gastric pH &lt;4 pretreatment increased to &gt;4 after a 2-mg/kg dose and remained above 4 for at least 15 hours.</p>
</div>
<div class="Section">
<a name="ID42"></a><a name="section-3.15"></a><p></p>
<h2>Clinical Trials</h2>
</div>
<div class="Section">
<a name="ID43"></a><a name="section-3.16"></a><p></p>
<h2>Active <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span></h2>
<p class="First"><a name="ID44"></a>In a multicenter, double-blind, controlled, US study of endoscopically diagnosed <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>, earlier healing was seen in the patients treated with oral ranitidine hydrochloride as shown in Table 3.</p>
<a name="ID45"></a><table width="100%">
<caption><span>Table 3 <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">Duodenal Ulcer</span> Patient Healing Rates</span></caption>
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<thead>
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" colspan="1" valign="top">
<br><br><br><br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">Oral </span><span class="Bold">Ranitidine </span><span class="Bold">Hydrochloride</span><span class="Bold"><span class="Sup">*</span></span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">Oral </span><span class="Bold">Placebo</span><span class="Bold"><span class="Sup">*</span></span><br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" colspan="1" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">Number </span><span class="Bold">Entered</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">Healed</span><span class="Bold">/ </span><span class="Bold">Evaluable</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">Number </span><span class="Bold">Entered</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">Healed</span><span class="Bold">/ </span><span class="Bold">Evaluable</span><br>
</td>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="5"><p class="First Footnote"><span class="Sup">*</span>All patients were permitted antacids as needed for relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p></td></tr>
<tr class="Last"><td align="left" colspan="5"><p class="First Footnote"><span class="Sup"></span><span class="Sup"></span><span class="Sup"></span><span class="Sup"></span><span class="Sup"></span><span class="Sup"></span><span class="Sup"></span><span class="Sup"></span><span class="Sup"></span><span class="Sup"></span><span class="Sup"></span><span class="Sup"></span><span class="Sup">†</span><span class="Italics">P</span>&lt;0.0001<br></p></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Outpatients Week 2<br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="middle">
<br>195<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">69/182<br>(38%)<span class="Sup">†</span><br><br>
</td>
<td class="Lrule Rrule Toprule" align="center" valign="middle">
<br>188<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">31/164<br>(19%)<br><br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Week 4<br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<br>137/187<br>(73%)<span class="Sup">†</span><br>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<br>76/168<br>(45%)</td>
</tr>
</tbody>
</table>
<p><a name="ID46"></a>In these studies, patients treated with oral ranitidine hydrochloride reported a reduction in both daytime and nocturnal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and they also consumed less antacid than the placebo-treated patients.</p>
<a name="ID47"></a><table width="99%">
<caption><span>Table 4 Mean Daily Doses of Antacid</span></caption>
<col width="33%">
<col width="33%">
<col width="33%">
<thead><tr class="First Last">
<td class="Botrule Rrule" align="left" colspan="1" valign="top"><br></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">Ulcer </span><span class="Bold">Healed</span><span class="Bold"><br></span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" valign="top">
<span class="Bold">Ulcer </span><span class="Bold">Not </span><span class="Bold">Healed</span><span class="Bold"><br></span>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Oral Ranitidine Hydrochloride <br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.06<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.71<br>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Oral placebo<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.71<br>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.43<br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section">
<a name="ID48"></a><a name="section-3.17"></a><p></p>
<h2>Pathological Hypersecretory Conditions (such as Zollinger-Ellison syndrome)</h2>
<p class="First"><a name="ID49"></a>Ranitidine hydrochloride inhibits gastric acid secretion and reduces occurrence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in patients with pathological hypersecretion associated with Zollinger-Ellison syndrome, <span class="product-label-link" type="condition" conceptid="4246284" conceptname="Systemic mast cell disease">systemic mastocytosis</span>, and other pathological hypersecretory conditions (e.g., postoperative, "short-gut" syndrome, idiopathic). Use of oral ranitidine hydrochloride was followed by healing of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in 8 of 19 (42%) patients who were intractable to previous therapy.</p>
<p>In a retrospective review of 52 Zollinger-Ellison patients given ranitidine hydrochloride as a continuous IV infusion for up to 15 days, no patients developed complications of acid-peptic disease such as <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or perforation. Acid output was controlled to           ≤10 mEq/h.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID50"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><a name="ID51"></a>Ranitidine injection is indicated in some hospitalized patients with pathological hypersecretory conditions or intractable <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>, or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID52"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><a name="ID53"></a>Ranitidine injection is contraindicated for patients known to have <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID54"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section">
<a name="ID55"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<ol>
<li>Symptomatic response to therapy with ranitidine hydrochloride does not preclude the presence of <span class="product-label-link" type="condition" conceptid="443387" conceptname="Malignant tumor of stomach">gastric malignancy</span>.</li>
<li>Since ranitidine hydrochloride is excreted primarily by the kidney, dosage should be adjusted in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (see <span class="Bold"><a href="#ID112">DOSAGE AND ADMINISTRATION</a></span>). Caution should be observed in patients with hepatic dysfunction since ranitidine hydrochloride is metabolized in the liver.</li>
<li>In controlled studies in normal volunteers, elevations in SGPT have been observed when H<span class="Sub">2</span>-antagonists have been administered intravenously at greater-than-recommended dosages for 5 days or longer. Therefore, it seems prudent in patients receiving IV ranitidine at dosages ≥100 mg 4 times daily for periods of 5 days or longer to monitor SGPT daily (from day 5) for the remainder of IV therapy.</li>
<li><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> in association with rapid administration of ranitidine injection has been reported rarely, usually in patients with factors predisposing to cardiac rhythm disturbances. Recommended rates of administration should not be exceeded (see <span class="Bold"><a href="#ID112">DOSAGE AND ADMINISTRATION</a></span>).</li>
<li>Rare reports suggest that ranitidine hydrochloride may precipitate acute porphyric attacks in patients with acute <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>. Ranitidine hydrochloride should therefore be avoided in patients with a history of acute <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="ID57"></a><a name="section-6.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First"><a name="ID58"></a>False-positive tests for urine protein with MULTISTIX<span class="Sup">®$</span> may occur during therapy with ranitidine hydrochloride, and therefore testing with sulfosalicylic acid is recommended.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID59"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><a name="ID60"></a>Ranitidine has been reported to affect the bioavailability of other drugs through several different mechanisms such as competition for renal tubular secretion, alteration of gastric pH, and inhibition of cytochrome P450 enzymes.</p>
</div>
<div class="Section">
<a name="ID61"></a><a name="section-6.4"></a><p></p>
<h2>Procainamide</h2>
<p class="First"><a name="ID62"></a>Ranitidine, a substrate of the renal organic cation transport system, may affect the clearance of other drugs eliminated by this route. High doses of ranitidine (e.g., such as those used in the treatment of Zollinger-Ellison syndrome) have been shown to reduce the renal excretion of procainamide and N-acetylprocainamide resulting in increased plasma levels of these drugs. Although this interaction is unlikely to be clinically relevant at usual ranitidine doses, it may be prudent to monitor for procainamide toxicity when administered with oral ranitidine at a dose exceeding 300 mg per day.</p>
</div>
<div class="Section">
<a name="ID63"></a><a name="section-6.5"></a><p></p>
<h2>Warfarin</h2>
<p class="First"><a name="ID64"></a>There have been reports of altered <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time among patients on concomitant warfarin and ranitidine therapy. Due to the narrow therapeutic index, close monitoring of increased or decreased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time is recommended during concurrent treatment with ranitidine.</p>
<p>Ranitidine may alter the absorption of drugs in which gastric pH is an important determinant of bioavailability. This can result in either an increase in absorption (e.g., triazolam, midazolam, glipizide) or a decrease in absorption (e.g., ketoconazole, atazanavir, delavirdine, gefitinib). Appropriate clinical monitoring is recommended.</p>
</div>
<div class="Section">
<a name="ID65"></a><a name="section-6.6"></a><p></p>
<h2>Atazanavir</h2>
<p class="First"><a name="ID66"></a>Atazanavir absorption may be impaired based on known interactions with other agents that increase gastric pH. Use with caution. See atazanavir label for specific recommendations.</p>
</div>
<div class="Section">
<a name="ID67"></a><a name="section-6.7"></a><p></p>
<h2>Delavirdine</h2>
<p class="First"><a name="ID68"></a>Delavirdine absorption may be impaired based on known interactions with other agents that increase gastric pH. Chronic use of H<span class="Sub">2</span>-receptor antagonists with delavirdine is not recommended.</p>
</div>
<div class="Section">
<a name="ID69"></a><a name="section-6.8"></a><p></p>
<h2>Gefitinib</h2>
<p class="First"><a name="ID70"></a>Gefitinib exposure was reduced by 44% with the coadministration of ranitidine and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> (dosed to maintain gastric pH above 5.0). Use with caution.</p>
</div>
<div class="Section">
<a name="ID71"></a><a name="section-6.9"></a><p></p>
<h2>Glipizide</h2>
<p class="First"><a name="ID72"></a>In diabetic patients, glipizide exposure was increased by 34% following a single 150 mg dose of oral ranitidine. Use appropriate clinical monitoring when initiating or discontinuing ranitidine.</p>
</div>
<div class="Section">
<a name="ID73"></a><a name="section-6.10"></a><p></p>
<h2>Ketoconazole</h2>
<p class="First"><a name="ID74"></a>Oral ketoconazole exposure was reduced by up to 95% when oral ranitidine was coadministered in a regimen to maintain a gastric pH of 6 or above. The degree of interaction with usual dose of ranitidine (150 mg twice daily) is unknown.</p>
</div>
<div class="Section">
<a name="ID75"></a><a name="section-6.11"></a><p></p>
<h2>Midazolam</h2>
<p class="First"><a name="ID76"></a>Oral midazolam exposure in 5 healthy volunteers was increased by up to 65% when administered with oral ranitidine at a dose of 150 mg twice daily. However, in another interaction study in 8 volunteers receiving IV midazolam, a 300 mg oral dose of ranitidine increased midazolam exposure by about 9%. Monitor patients for excessive or prolonged sedation when ranitidine is coadministered with oral midazolam.</p>
</div>
<div class="Section">
<a name="ID77"></a><a name="section-6.12"></a><p></p>
<h2>Triazolam</h2>
<p class="First"><a name="ID78"></a>Triazolam exposure in healthy volunteers was increased by approximately 30% when administered with oral ranitidine at a dose of 150 mg twice daily. Monitor patients for excessive or prolonged sedation.</p>
</div>
<div class="Section">
<a name="ID79"></a><a name="section-6.13"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><a name="ID80"></a>There was no indication of tumorigenic or carcinogenic effects in life-span studies in mice and rats at oral dosages up to 2,000 mg/kg/day.</p>
<p>Ranitidine was not mutagenic in standard bacterial tests (<span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span>, <span class="Italics">Escherichia coli</span>) for mutagenicity at concentrations up to the maximum recommended for these assays.</p>
<p>In a dominant lethal assay, a single oral dose of 1,000 mg/kg to male rats was without effect on the outcome of 2 matings per week for the next 9 weeks.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="ID81"></a><a name="section-6.14"></a><p></p>
<h2>Pregnancy</h2>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="ID82"></a><a name="section-6.15"></a><p></p>
<h2>Teratogenic Effects</h2>
<p class="First"><a name="ID83"></a><span class="Italics">Pregnancy Category B. </span></p>
<p>Reproduction studies have been performed in rats and rabbits at oral doses up to 160 times the human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to ranitidine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID84"></a><a name="section-6.16"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First"><a name="ID85"></a>Ranitidine is secreted in human milk. Caution should be exercised when ranitidine hydrochloride is administered to a nursing mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID86"></a><a name="section-6.17"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First"><a name="ID87"></a>The safety and effectiveness of ranitidine injection have been established in the age-group of 1 month to 16 years for the treatment of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>. Use of ranitidine hydrochloride in this age-group is supported by adequate and well-controlled studies in adults, as well as additional pharmacokinetic data in pediatric patients, and an analysis of the published literature.</p>
<p>Safety and effectiveness in pediatric patients for the treatment of pathological hypersecretory conditions have not been established.</p>
<p>Limited data in neonatal patients (less than 1 month of age) receiving ECMO suggest that ranitidine hydrochloride may be useful and safe for increasing gastric pH for patients at risk of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID88"></a><a name="section-6.18"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First"><a name="ID89"></a>Clinical studies of ranitidine injection did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects. However, in clinical studies of oral formulations of ranitidine hydrochloride, of the total number of subjects enrolled in US and foreign controlled clinical trials, for which there were subgroup analyses, 4,197 were 65 and over, while 899 were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>This drug is known to be substantially excreted by the kidney and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, caution should be exercised in dose selection, and it may be useful to monitor renal function (see <span class="Bold">CLINICAL PHARMACOLOGY: Pharmacokinetics: <a href="#ID88">Geriatric Use</a> and DOSAGE AND ADMINISTRATION: <a href="#ID124">Dosage Adjustment for Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID90"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><a name="ID91"></a>Transient <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at the site of IM injection has been reported. Transient local burning or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> has been reported with IV administration of ranitidine hydrochloride.</p>
<p>The following have been reported as events in clinical trials or in the routine management of patients treated with oral or parenteral ranitidine hydrochloride. The relationship to therapy with ranitidine hydrochloride has been unclear in many cases. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, sometimes severe, seems to be related to administration of ranitidine hydrochloride.</p>
<div class="Section">
<a name="ID92"></a><a name="section-7.1"></a><p></p>
<h2>Central Nervous System</h2>
<p class="First"><a name="ID93"></a>Rarely, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>. Rare cases of reversible <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> have been reported, predominantly in severely ill elderly patients. Rare cases of reversible <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> suggestive of a change in accommodation have been reported. Rare reports of reversible involuntary motor disturbances have been received.</p>
</div>
<div class="Section">
<a name="ID94"></a><a name="section-7.2"></a><p></p>
<h2>Cardiovascular</h2>
<p class="First"><a name="ID95"></a>As with other H<span class="Sub">2</span>-blockers, rare reports of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> such as <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, and premature ventricular beats.</p>
</div>
<div class="Section">
<a name="ID96"></a><a name="section-7.3"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First"><a name="ID97"></a><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and rare reports of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</p>
</div>
<div class="Section">
<a name="ID98"></a><a name="section-7.4"></a><p></p>
<h2>Hepatic</h2>
<p class="First"><a name="ID99"></a>In normal volunteers, SGPT values were increased to at least twice the pretreatment levels in 6 of 12 subjects receiving 100 mg intravenously 4 times daily for 7 days, and in 4 of 24 subjects receiving 50 mg intravenously 4 times daily for 5 days. There have been occasional reports of hepatocellular, cholestatic, or mixed <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, with or without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. In such circumstances, ranitidine should be immediately discontinued. These events are usually reversible, but in rare circumstances <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has occurred. Rare cases of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> have also been reported.</p>
</div>
<div class="Section">
<a name="ID100"></a><a name="section-7.5"></a><p></p>
<h2>Musculoskeletal</h2>
<p class="First"><a name="ID101"></a>Rare reports of <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span> and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>.</p>
<p><span class="Bold">Hematologic</span></p>
<p>Blood count changes (<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>) have occurred in a few patients. These were usually reversible. Rare cases of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, sometimes with <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">marrow hypoplasia</span>, and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> and exceedingly rare cases of acquired immune <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> have been reported.</p>
</div>
<div class="Section">
<a name="ID102"></a><a name="section-7.6"></a><p></p>
<h2>Endocrine</h2>
<p class="First"><a name="ID103"></a>Controlled studies in animals and humans have shown no stimulation of any pituitary hormone by ranitidine hydrochloride and no antiandrogenic activity, and cimetidine-induced <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> in hypersecretory patients have resolved when ranitidine hydrochloride has been substituted. However, occasional cases of <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> and <span class="product-label-link" type="condition" conceptid="4087317" conceptname="Lack of libido">loss of libido</span> have been reported in male patients receiving ranitidine hydrochloride, but the incidence did not differ from that in the general population. Rare cases of breast symptoms and conditions, including <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span> and <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, have been reported in both males and females.</p>
</div>
<div class="Section">
<a name="ID104"></a><a name="section-7.7"></a><p></p>
<h2>Integumentary</h2>
<p class="First"><a name="ID105"></a><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, including rare cases of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>. Rare cases of <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> and <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>.</p>
</div>
<div class="Section">
<a name="ID106"></a><a name="section-7.8"></a><p></p>
<h2>Respiratory</h2>
<p class="First"><a name="ID107"></a>A large epidemiological study suggested an increased risk of developing <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> in current users of histamine-2-receptor antagonists (H<span class="Sub">2</span>RAs) compared to patients who had stopped H<span class="Sub">2</span>RA treatment, with an observed adjusted relative risk of 1.63 (95% CI, 1.07 to 2.48). However, a causal relationship between use of H<span class="Sub">2</span>RAs and <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> has not been established.</p>
</div>
<div class="Section">
<a name="ID108"></a><a name="section-7.9"></a><p></p>
<h2>Other</h2>
<p class="First"><a name="ID109"></a>Rare cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>), <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="4102631" conceptname="Acute interstitial nephritis">acute interstitial nephritis</span>, and small increases in serum creatinine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID110"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><a name="ID111"></a>There has been virtually no experience with overdosage with ranitidine injection and limited experience with oral doses of ranitidine. Reported acute ingestions of up to 18 g orally have been associated with transient adverse effects similar to those encountered in normal clinical experience (see <span class="Bold"><a href="#ID90">ADVERSE REACTIONS</a></span>). In addition, abnormalities of gait and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> have been reported.</p>
<p>When overdosage occurs, clinical monitoring and supportive therapy should be employed.</p>
<p>Studies in dogs receiving dosages of ranitidine hydrochloride in excess of 225 mg/kg/day have shown muscular <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and rapid respiration. Single oral doses of 1,000 mg/kg in mice and rats were not lethal. Intravenous LD<span class="Sub">50</span> values in mice and rats were 77 and 83 mg/kg, respectively.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID112"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section">
<a name="ID113"></a><a name="section-9.1"></a><p></p>
<h2>Parenteral Administration</h2>
<p class="First"><a name="ID114"></a>In some hospitalized patients with pathological hypersecretory conditions or intractable <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span>, or in patients who are unable to take oral medication, ranitidine hydrochloride may be administered parenterally according to the following recommendations:</p>
</div>
<div class="Section">
<a name="ID115"></a><a name="section-9.2"></a><p></p>
<h2>Intramuscular Injection</h2>
<p class="First"><a name="ID116"></a>50 mg (2 mL) every 6 to 8 hours. (No dilution necessary.)</p>
</div>
<div class="Section">
<a name="ID117"></a><a name="section-9.3"></a><p></p>
<h2>Intermittent Intravenous Injection</h2>
<ol class="LittleAlpha"><li><span class="Bold Italics">Intermittent Bolus </span></li></ol>
<p class="First"><a name="ID119"></a>50 mg (2 mL) every 6 to 8 hours. Dilute ranitidine injection, 50 mg, in 0.9% sodium chloride injection or other compatible IV solution (see <span class="Bold"><a href="#ID126">Stability</a></span>) to a concentration no greater than 2.5 mg/mL (20 mL). Inject at a rate no greater than 4 mL/min (5 minutes).</p>
<ol class="LittleAlpha"><li><span class="Bold"><span class="Italics">Intermittent Infusion</span></span></li></ol>
<p><a name="ID137"></a>50 mg (2 mL) every 6 to 8 hours. Dilute ranitidine injection, 50 mg, in 5% dextrose injection or other compatible IV solution (see <span class="Bold"><a href="#ID126">Stability</a></span>) to a concentration no greater than 0.5 mg/mL (100 mL). Infuse at a rate no greater than 5 to 7 mL/min (15 to 20 minutes).</p>
<p>In some patients it may be necessary to increase dosage. When this is necessary, the increases should be made by more frequent administration of the dose, but generally should not exceed 400 mg/day.</p>
</div>
<div class="Section">
<a name="ID120"></a><a name="section-9.4"></a><p></p>
<h2>Continuous Intravenous Infusion</h2>
<p class="First"><a name="ID121"></a>Add ranitidine injection to 5% dextrose injection or other compatible IV solution (see <span class="Bold"><a href="#ID126">Stability</a></span>). Deliver at a rate of 6.25 mg/hour (e.g., 150 mg [6 mL] of ranitidine injection in 250 mL of 5% dextrose injection at 10.7 mL/hour).</p>
<p>For Zollinger-Ellison patients, dilute ranitidine injection in 5% dextrose injection or other compatible IV solution (see <span class="Bold"><a href="#ID126">Stability</a></span>) to a concentration no greater than 2.5 mg/mL. Start the infusion at a rate of 1.0 mg/kg/hour. If after 4 hours either a measured gastric acid output is &gt;10 mEq/hour or the patient becomes symptomatic, the dose should be adjusted upward in 0.5 mg/kg/hour increments, and the acid output should be remeasured. Dosages up to 2.5 mg/kg/hour and infusion rates as high as 220 mg/hour have been used.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID122"></a><a name="section-9.5"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First"><a name="ID123"></a>While limited data exist on the administration of IV ranitidine to children, the recommended dose in pediatric patients is for a total daily dose of 2 to 4 mg/kg, to be divided and administered every 6 to 8 hours, up to a maximum of 50 mg given every 6 to 8 hours. This recommendation is derived from adult clinical studies and pharmacokinetic data in pediatric patients. Limited data in neonatal patients (less than 1 month of age) receiving ECMO have shown that a dose of 2 mg/kg is usually sufficient to increase gastric pH to &gt;4 for at least 15 hours. Therefore, doses of 2 mg/kg given every 12 to 24 hours or as a continuous infusion should be considered.</p>
</div>
<div class="Section">
<a name="ID124"></a><a name="section-9.6"></a><p></p>
<h2>Dosage Adjustment for Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First"><a name="ID125"></a>The administration of ranitidine as a continuous infusion has not been evaluated in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. On the basis of experience with a group of subjects with severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> treated with ranitidine hydrochloride, the recommended dosage in patients with a creatinine clearance &lt;50 mL/min is 50 mg every 18 to 24 hours. Should the patient’s condition require, the frequency of dosing may be increased to every 12 hours or even further with caution. Hemodialysis reduces the level of circulating ranitidine. Ideally, the dosing schedule should be adjusted so that the timing of a scheduled dose coincides with the end of hemodialysis.</p>
<p>Elderly patients are more likely to have decreased renal function, therefore caution should be exercised in dose selection, and it may be useful to monitor renal function (see <span class="Bold">CLINICAL PHARMACOLOGY: Pharmacokinetics: <a href="#ID88">Geriatric Use</a></span>and <span class="Bold">PRECAUTIONS: <a href="#ID88">Geriatric Use</a>).</span></p>
</div>
<div class="Section">
<a name="ID126"></a><a name="section-9.7"></a><p></p>
<h2>Stability</h2>
<p class="First"><a name="ID127"></a>Undiluted, ranitidine injection tends to exhibit a yellow color that may intensify over time without adversely affecting potency. Ranitidine injection is stable for 48 hours at room temperature when added to or diluted with most commonly used IV solutions, e.g., 0.9% sodium chloride injection, 5% dextrose injection, 10% dextrose injection, lactated ringer's injection, or 5% sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> injection.</p>
</div>
<div class="Section">
<a name="ID128"></a><a name="section-9.8"></a><p></p>
<h2>Note</h2>
<p class="First"><a name="ID129"></a>Parenteral drug products should be inspected visually for particulate matter and discoloration before administration whenever solution and container permit.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID130"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><a name="ID131"></a>Ranitidine Injection USP, 25 mg/mL, containing phenol 0.5% as preservative, is available as follows:</p>
<p>NDC-65841-763-02, 2-mL single-use vials (10 Vials per carton)</p>
<p>NDC-65841-764-06, 6-mL multi-dose vials (Single)</p>
<div class="Section">
<a name="ID132"></a><a name="section-10.1"></a><p></p>
<h2>Storage</h2>
<p class="First"><a name="ID133"></a>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Do not freeze. Protect from light.</p>
<p>Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat; however, brief exposure up to 40°C does not adversely affect the product. Protect from freezing. </p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p><span class="Sup">$</span>MULTISTIX<span class="Sup">® </span>is the registered trademark of Siemens healthcare diagnostics.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID134"></a><a name="section-11"></a><p></p>
<p class="First"><a name="ID135"></a><span class="Bold">Manufactured by:</span></p>
<p>Cadila Healthcare Ltd.</p>
<p>Ahmedabad, India</p>
<p>Rev.: 07/13</p>
<p>Revision Date : 31/07/2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID138"></a><a name="section-12"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><a name="ID139"></a>NDC-65841-763-02</p>
<p>Ranitidine Injection, USP</p>
<p> 2-mL single-use vials</p>
<p> Vial Label</p>
<div class="Figure">
<img alt="vial label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9268c1df-bcf3-4899-896d-044492802a33&amp;name=ranitidininjmanufact-figure-02.jpg"><p class="MultiMediaCaption">figure02</p>
</div>
<p><a name="ID141"></a>NDC-65841-763-02</p>
<p> Ranitidine Injection, USP</p>
<p> 2-mL single-use vials</p>
<p> Carton Label</p>
<p> 10 X 2 mL vial</p>
<p> </p>
<div class="Figure">
<img alt="carton label single-use" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9268c1df-bcf3-4899-896d-044492802a33&amp;name=ranitidininjmanufact-figure-03.jpg"><p class="MultiMediaCaption">figure03</p>
</div>
<p><a name="ID143"></a>NDC-65841-764-06</p>
<p> Ranitidine Injection, USP</p>
<p>6-mL multi-dose vials</p>
<p>Vial Label</p>
<div class="Figure">
<img alt="Vial Label multidose" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9268c1df-bcf3-4899-896d-044492802a33&amp;name=ranitidininjmanufact-figure-04.jpg"><p class="MultiMediaCaption">figure 04</p>
</div>
<p><a name="ID145"></a>NDC-65841-764-06</p>
<p> Ranitidine Injection, USP</p>
<p>6-mL multi-dose vials</p>
<p>Carton Label</p>
<div class="Figure">
<img alt="carton label multidose" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9268c1df-bcf3-4899-896d-044492802a33&amp;name=ranitidininjmanufact-figure-05.jpg"><p class="MultiMediaCaption">figure 05</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RANITIDINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">ranitidine hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:65841-763</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>RANITIDINE HYDROCHLORIDE</strong> (RANITIDINE) </td>
<td class="formItem">RANITIDINE</td>
<td class="formItem">25 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PHENOL</strong></td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM PHOSPHATE, MONOBASIC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:65841-763-02</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091534</td>
<td class="formItem">03/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RANITIDINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">ranitidine hydrochloride injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:65841-764</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>RANITIDINE HYDROCHLORIDE</strong> (RANITIDINE) </td>
<td class="formItem">RANITIDINE</td>
<td class="formItem">25 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PHENOL</strong></td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM PHOSPHATE, MONOBASIC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:65841-764-06</td>
<td class="formItem">6 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091534</td>
<td class="formItem">03/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cadila Healthcare Limited
							(918596198)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Cadila Healthcare Limited (918596198)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cadila Healthcare Limited</td>
<td class="formItem"></td>
<td class="formItem">918596198</td>
<td class="formItem">Analysis(65841-764), Manufacture(65841-764)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b61ba4f6-87b9-4d3e-a175-2b6a0b9626b4</div>
<div>Set id: 9268c1df-bcf3-4899-896d-044492802a33</div>
<div>Version: 2</div>
<div>Effective Time: 20130805</div>
</div>
</div> <div class="DistributorName">Cadila Healthcare Limited</div></p>
</body></html>
